International law firm CMS has advised Autolomous, a developer of innovative software for cell and gene therapy manufacturers, on its seed funding round led by a US-European investor consortium.

Release posted on the CMS website:

The funding will enable Autolomous to build its capacity to meet rapidly increasing customer demands across Europe and the US, expand the functionality of its software solutions platform, AutoloMATE, and complete the establishment of its fully integrated ecosystem.

Theo Godfrey, Corporate partner at CMS UK, comments: “We are delighted to have successfully advised Autolomous on its first round of funding. It has been a great opportunity to work with an incredibly smart, ambitious and forward-looking team and we wish them the very best as they look to deploy this funding optimally. As a member of equIP Life Sciences, our accelerator programme focussed on start-ups in the life sciences sector, Autolomous will continue receive our support as the company develops.”

Alexander Seyf, CEO of Autolomous adds: “It has been a great pleasure to work with a top tier law firm like CMS, whose advice is often out of reach for start-ups. Theo and his team have been a great help to us. The CMS equIP Life Sciences Programme has allowed us to access lawyers who understand the needs of a start-up in the cell and gene therapy space and the scale of what we’re trying to achieve. With our legal foundations firmly in place, we can now concentrate on the commercial opportunities that will follow.”